Nexstim (NXTMH) H2 2025 earnings summary

Executive summary

• Achieved 26% revenue growth in 2025 to EUR 11 million, with all segments contributing and research & neuroscience sales up 213%.

• Delivered record system sales, launched NBS 6 with FDA and MDR approvals, and expanded global reach through partnerships with Brainlab and Sinaptica.

• Achieved first full-year profit, with positive EBIT and strong cost control.

• Set strategic objectives for 2026: profitable growth, partnership expansion, and technology leadership.

Financial highlights

• Total revenue reached EUR 11 million in 2025, with diagnostics up 24% (EUR 5.5m), therapy up 12% (EUR 4.5m), and research/neuroscience up 213% (EUR 1m).

• Gross margin was 77.1% (EUR 8.5m), EBITDA EUR 1.7m (+430%), and net profit EUR 0.6m.

• Operating expenses grew only 1% to EUR 8.2m; operating cash flow was EUR 1.7m; year-end cash balance EUR 2.7m; equity ratio at 39.7%.

• Earnings per share: EUR 0.08 (FY2025) vs. EUR -0.13 (FY2024).

Outlook and guidance

• Expects net sales growth and improved operating profit in 2026, with long-term objectives of >20% annual net sales growth and >20% operating profit margin.

• Focus on profitable growth, strengthening partnerships, and advancing technology leadership.